These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 365122)

  • 1. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
    Arch Gen Psychiatry; 1978 Mar; 35(3):335-40. PubMed ID: 365122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of naltrexone in 155 heroin ex-addicts.
    Volavka J; Resnick RB; Kestenbaum RS; Freedman AM
    Biol Psychiatry; 1976 Dec; 11(6):679-85. PubMed ID: 999987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonidine and opiate receptor antagonists in the treatment of heroin addiction.
    Gerra G; Marcato A; Caccavari R; Fontanesi B; Delsignore R; Fertonani G; Avanzini P; Rustichelli P; Passeri M
    J Subst Abuse Treat; 1995; 12(1):35-41. PubMed ID: 7752296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Narcotic antagonists: naltrexone progress report: introduction.
    Renault PF
    NIDA Res Monogr; 1976 Sep; (9):1-3. PubMed ID: 794713
    [No Abstract]   [Full Text] [Related]  

  • 5. Factors influencing success in an antagonistic treatment program.
    Parwatikar S; Crawford J; Nelkupa JV; De Gracia C
    NIDA Res Monogr; 1976 Sep; (9):77-81. PubMed ID: 794725
    [No Abstract]   [Full Text] [Related]  

  • 6. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone and naltrexone in the treatment of heroin dependence.
    Greenstein RA; Resnick RB; Resnick E
    Psychiatr Clin North Am; 1984 Dec; 7(4):671-9. PubMed ID: 6522309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone: the clinical investigator's dilemma.
    Ling W
    NIDA Res Monogr; 1978; (19):308-14. PubMed ID: 106297
    [No Abstract]   [Full Text] [Related]  

  • 10. Five-year follow-up of opiate addicts with naltrexone and behavior therapy.
    Rawson RA; Tennant FS
    NIDA Res Monogr; 1984 Mar; 49():289-95. PubMed ID: 6434974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of heroin-dependent persons with antagonists: current status.
    Renault PF
    NIDA Res Monogr; 1981; 28():11-22. PubMed ID: 6791000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Operant analysis of human heroin self-administration and the effects of naltrexone.
    Mello NK; Mendelson JH; Kuehnle JC; Sellers MS
    J Pharmacol Exp Ther; 1981 Jan; 216(1):45-54. PubMed ID: 7452507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use.
    Longshore D; Annon J; Anglin MD; Rawson RA
    Addiction; 2005 Aug; 100(8):1131-9. PubMed ID: 16042643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone for heroin dependence treatment in St. Petersburg, Russia.
    Krupitsky EM; Zvartau EE; Masalov DV; Tsoi MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
    J Subst Abuse Treat; 2004 Jun; 26(4):285-94. PubMed ID: 15182893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone in the treatment of opiate dependence.
    Resnick RB; Washton AM; Thomas MA; Kestenbaum RS
    NIDA Res Monogr; 1978; (19):321-32. PubMed ID: 218108
    [No Abstract]   [Full Text] [Related]  

  • 19. Update of naltrexone treatment.
    O'Brien CP; Greenstein R; Woody GE
    NIDA Res Monogr; 1978; (19):315-20. PubMed ID: 218107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.